Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emile Voest

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Cell Reports|March 8, 2016
Plasticity between Epithelial and Mesenchymal States Unlinks EMT from Metastasis-Enhancing Stem Cell CapacityEvelyne Beerling, Daniëlle Seinstra, Elzo de Wit, et al.
The Oncologist|December 17, 2013
Adding preoperative radiotherapy plus cetuximab to perioperative chemotherapy for resectable esophageal adenocarcinoma: a single-center prospective phase II trialInge Ubink, Pieter van der Sluis, Marguerite Schipper, et al.
JCO Precision Oncology|January 4, 2019
Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyPam K Mangat, Susan Halabi, Suanna S Bruinooge, et al.
Nature Medicine|April 20, 2022
Delivering precision oncology to patients with cancerJoaquin Mateo, Lotte Steuten, Philippe Aftimos, et al.
Cancer Medicine|April 29, 2023
Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinomaElisabeth G E de Vries, Josef Rüschoff, Martijn Lolkema, et al.
ESMO Open|April 22, 2020
Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancerRhode Bijlsma, Roel Wouters, Hester Wessels, et al.
Nature Communications|June 24, 2020
Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumoursJoão M Fernandes Neto, Ernest Nadal, Evert Bosdriesz, et al.
Genome Biology|October 22, 2011
Chromothripsis is a common mechanism driving genomic rearrangements in primary and metastatic colorectal cancerWigard P Kloosterman, Marlous Hoogstraat, Oscar Paling, et al.
Journal of Internal Medicine|August 29, 2023
Precision cancer medicine: Concepts, current practice, and future developmentsAnders Edsjö, Louise Holmquist, Birgit Geoerger, et al.
ESMO Open|August 30, 2017
Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribersJosep Tabernero, Malvika Vyas, Rosa Giuliani, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Cell Reports|March 8, 2016
Plasticity between Epithelial and Mesenchymal States Unlinks EMT from Metastasis-Enhancing Stem Cell CapacityEvelyne Beerling, Daniëlle Seinstra, Elzo de Wit, et al.
The Oncologist|December 17, 2013
Adding preoperative radiotherapy plus cetuximab to perioperative chemotherapy for resectable esophageal adenocarcinoma: a single-center prospective phase II trialInge Ubink, Pieter van der Sluis, Marguerite Schipper, et al.
JCO Precision Oncology|January 4, 2019
Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyPam K Mangat, Susan Halabi, Suanna S Bruinooge, et al.
Nature Medicine|April 20, 2022
Delivering precision oncology to patients with cancerJoaquin Mateo, Lotte Steuten, Philippe Aftimos, et al.
Cancer Medicine|April 29, 2023
Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinomaElisabeth G E de Vries, Josef Rüschoff, Martijn Lolkema, et al.
ESMO Open|April 22, 2020
Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancerRhode Bijlsma, Roel Wouters, Hester Wessels, et al.
Nature Communications|June 24, 2020
Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumoursJoão M Fernandes Neto, Ernest Nadal, Evert Bosdriesz, et al.
Genome Biology|October 22, 2011
Chromothripsis is a common mechanism driving genomic rearrangements in primary and metastatic colorectal cancerWigard P Kloosterman, Marlous Hoogstraat, Oscar Paling, et al.
Journal of Internal Medicine|August 29, 2023
Precision cancer medicine: Concepts, current practice, and future developmentsAnders Edsjö, Louise Holmquist, Birgit Geoerger, et al.
ESMO Open|August 30, 2017
Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribersJosep Tabernero, Malvika Vyas, Rosa Giuliani, et al.
Pageof 3